Keywords
PET/CT
Treatment
Non-invasive surgery
Radiomics
Computed tomography
Submitted : 2023-04-17
Accepted : 2023-05-02
Published : 2023-05-17
Abstract
Lung cancer relatively common in Peru. PET/CT is a useful tool in the staging and follow-up of the treatment of lung tumors. There is currently enough evidence to affirm that this technology helps in adjusting treatment and increasing the survival rate of the patients. A descriptive review of the relevant articles recently published on the subject was carried out. It is concluded that PET/CT is useful in the staging and follow-up of the proposed treatment for patients with non-small cell lung cancer. This malignant tumor is also often discovered and diagnosed at an advanced stage.
References
Fischer B, Lassen U, Mortensen J, et al., 2009, Preoperative Staging of Lung Cancer with Combined PET-CT. The New England Journal of Medicine, 361(1): 32–39.
Farsad M, 2020, FDG PET/CT in the Staging of Lung Cancer. Current Radiopharmaceuticals, 13(3): 195–203.
World Cancer Observatory, n.d., viewed July 19, 2022, https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-factsheet.pdf
National Institute of Neoplastic Diseases, 2019, Health Manual: Cancer Prevention, https://portal.inen.sld.pe/wp-content/uploads/2019/10/MANUAL-PREVENCION-CANCER_final-16.01.19.pdf
Lima N, Cancela M, Becerra D, et al., 2022, Spatial Assessment of Advanced-Stage Diagnosis and Lung Cancer Mortality in Brazil. Plos One, 17(3): e0265321. https://doi.org/10.1371/journal.pone.0265321
Mu W, Jiang L, Zhang J, et al., 2020, Non Invasive Decision Support for NSCLC Treatment Using PET/CT Radiomics. Nature Communications, 11: 5228. https://doi.org/10.1038/s41467-020-19116-x
Maurer M, Kasmann L, Fleischmann D, et al., 2022, PET/CT-Based Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer in Multicenter yDEGRO ARO 2017-01 Cohort Study. Radiation Oncology, 17: 29. https://doi.org/10.1186/s13014-022-01997-5
Han Y, Ma Y, Wu Z, et al., 2020, Histologic Subtype Classification of Non-Small Cell Lung Cancer Using PET/CT Images. European Journal of Nuclear Medicine and Molecular Imaging. 48: 350–360. https://doi.org/10.1007/s00259-020-04771-5
Popat S, Navani N, Smit E, et al., 2021, Navigating Diagnostic and Treatment Decisionsin Non-Small Cell Lung Cancer: Expert Commentary onthe Multidisciplinary Team Approach. The Oncologist, 26(2): e306–e315. https://academic.oup.com/oncolo/article/26/2/e306/6445376
Kaseda K, 2020, Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature. Diagnostics, 10(8): 561. https://doi.org/10.3390/diagnostics10080561
Chan J, Yu P, Lau R, Ng C, 2020, Hybrid Operating Room—Onestop for Diagnosis, Staging and Treatment of Early Stage NSCLC. J Thorac Dis, 12(2): 123–131.
Machado T, Altmayer S, Watte G, et al., 2020, 18F-FDG PET/CT and Whole-Body MRI Diagnostic Performance in M Staging for Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. European Radiology, 30: 3641–3649.
Rossi G, Russo A, Tagliamento M, et al., 2020, Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers, 12(5): 1125. https://doi.org/10.3390/cancers12051125
Al-Ibraheem A, Hirmas N, Fanti S, et al., 2021, Impact of 18F-FDG PET/CT, CT andEBUS/ TBNA on Preoperative Mediastinal Nodal Staging of NSCLC. BMC Medical Imaging 21: 49. https://doi.org/10.1186/s12880-021-00580-w
Osarogiagbon R, 2018, Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications. Journal of Thoracic Oncology, 13: 10S.
Hochhegger B, Tronco G, Irion K, et al., PET/CT Imaging in Lung Cancer: Indications and Findings. J Bras Pneumol, 41(3): 264–274. https://doi.org/10.1590/S1806-37132015000004479
Zhao L, He Z, Zhong X, et al., 2012, 18FDG-PET/CT for Detection of Mediastinal Nodal Metastasis in Non-Small Cell Lung Cancer: A Meta-Analysis. Surgical Oncology, 21: 230–236.
Osman A, Korashi H, 2020, PET/CT Implication on Bronchogeniccarcinoma TNM Staging and Follow-up using RECIST/PERCIST Criteria: A Comparative Study with CT. Egyptian Journal of Radiology and Nuclear Medicine, 51: 16. https://doi.org/10.1186/s43055-020-0133-5
Kandathil A, Kay F, Butt Y, et al., 2018, Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Radiographics, 38(7): 2134–2149. https://doi.org/10.1148/rg.2018180060
De Cecco CN, Burchett P, van Assen M, et al., Rationale and Design of a Prospective Study on the First Integrated PET/Dual Energy CT system for Staging and Image-Based Radiation Therapy Planning of Lung Cancer. European Radiology Experimental, 2: 15. https://doi.org/10.1186/s41747-018-0047-4
Lim C, Park S, Kim H, et al., 2022, Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy. Cancers, 14(3): 632. https:// doi.org/10.3390/cancers14030632
Zhu X, Liao C, Penney B, et al., 2017, Prognostic Value of Quantitative PET/CT in Patients with a Non-Small Cell Lung Cancer and Another Primary Cancer. Nuclear Medicine Communications, 38: 185–192.
Dashevsky B, Zhang C, Yan L, et al., 2017, Whole Body Metabolic Tumor Volume is a Prognostic Marker in Patients with Newly Diagnosed Stage 3B Non-Small Cell Lung Cancer, Confirmed with External Validation. European Journal of Hybrid Imaging, 1(1): 8.
Borrelli P, Ly J, Kaboteh R, et al., 2021, AI-based Detection of Lung Lesions in [18F] FDG PET-CT from Lung Cancer Patients. EJNMMI Physics, 8: 32. https://doi.org/10.1186/s40658-021-00376-5
Finkle J, Penney B, Pu Y, 2018, An Updated and Validated PET/CT Volumetric Prognostic Index for Non-Small Cell Lung Cancer. Lung Cancer Journal. https://doi.org/10.1016/j.lungcan.2018.07.019
Lababede O, Meziane M, 2018, The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. The Oncologist, 23(7): 844–848.
Tosi D, Pieropan S, Cattoni M, et al., 2021, Prognostic Value of 18F-FDGPET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients. Clin Nuc Med, 46(8): 621–626.
Lammertsma A, 2018, Forward to the Past: The Case for Quantitative PET Imaging. J Nucl Med, 58(7): 1019–1024. https://doi.org/10.2967/jnumed.116.188029
Hua J, Li L, Liu L, et al., 2021, The Diagnostic Value of Metabolic, Morphological and Heterogeneous Parameters of 18F-FDG PET/CT in Mediastinal Lymph Node Metastasis of Non-Small Cell Lung Cancer. Nuclear Medicine Communications. 42(11): 1247–1253. https://doi.org/10.1097/MNM.0000000000001456
Lee S, Kim S, 2022, Is Delayed Image of 18F-FDG PET/CT Necessary for Mediastinal Lymph Node Staging in Non–Small Cell Lung Cancer Patients? Clinical Nuclear Medicine, 47(5): 414–421. https://doi.org/10.1097/RLU.0000000000004110
Eze C, Schmidt-Hegemann N, Sawicki L, et al., 2021, PET/CT Imaging for Evaluation of Multimodal Treatment Efficacy and Toxicity in Advanced NSCLC—Current State and Future Directions. European Journal of Nuclear Medicine and Molecular Imaging. 48: 3975–3989. https://doi.org/10.1007/s00259-021-05211-8
Gamal G, 2021, The Usefulness of 18F-FDG PET/CT in Follow-up and Recurrence Detection for Patients with Lung Carcinoma and its Impact on the Survival Outcome. Egyptian Journal of Radiology and Nuclear Medicine, 52: 121. https://doi.org/10.1186/s43055-021-00504-2
Zheng K, Wang X, Jiang C, et al., 2021, Pre-Operative Prediction of Mediastinal Node Metastasis Using Radiomics Model Based on 18F-FDG PET/CT of the Primary Tumor in Non-Small Cell Lung Cancer Patients. Frontiers in Medicine, 8: 673876. https://doi.org/10.3389/fmed.2021.673876
Jahangiri P, Dreyfuss A, Duan F, et al., 2021, Implementation of FDG-PET/CT Imaging Methodology for Quantification of Inflammatory Response in Patients with Locally Advanced Non-Small Cell Lung Cancer: Results from the ACRIN 6668/RTOG0235 Trial. Am J Nucl Med Mol Imaging, 11(5): 415–427.
Fledelius J, Khalil A, Hjorthaug K, et al., 2016, Inter-Observer Agreement Improves with PERCIST 1.0 as Opposed to Qualitative Evaluation in Non-Small Cell Lung Cancer Patients Evaluated with F-18-FDG PET/CT Early in the Course of Chemo-Radiotherapy. EJNMMI Research, 6: 71. https://doi.org/10.1186/s13550-016-0223-6
Guberina M, Eberhardt W, Stuschke M, et al., 2019, Pretreatment Metabolic Tumor Volume in Stage III A/B Non-Small-Cell Lung Cancer Uncovers Differences in Effectiveness of Definitive Radio Chemotherapy Schedules: Analysis of the ESPATUE Randomized Phase 3 Trial. European Journal of Nuclear Medicine and Molecular Imaging [Internet]. 2019 [Consultado 2022Jul 19]. https://doi.org/10.1007/s00259-019-4270-x
Horn K, Thomas H, Vesselle H, et al., 2021, Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients with Locally Advanced Non–Small Cell Lung Cancer. Clin Nucl Med, 46: 861–871. https://doi.org/10.1097/RLU.0000000000003774
Zhou J, Zou S, Kuang D, et al., 2021, A Novel Approach using FDG PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients with Non-Small Cell Lung Cancer. Front. Oncol, https://doi.org/10.3389/fonc.2021.769272
Valentinuzzi D, Vrankar M, Boc N, et al., 2020, [18F] FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab. Radiol Oncol. 54(3): 285–294. https://doi.org/10.2478/raon-2020-0042
Teixidó C, Vilariño N, Reyes R, et al., 2018, PD-L1 Expression Testing in Non-Small Cell Lung Cancer. Therapeutic Advances in Medical Oncology. 10: 1–17.
Han Y, Xiao H, Zhou Z, et al., 2015, Cost-Effectiveness Analysis of Strategies Introducing Integrated 18F-FDG PET/CT into the Mediastinal Lymph Node Staging of Non-Small-Cell Lung Cancer. Nuclear Medicine Communications. 36: 234–241.
Johnson A, Norman R, Piccolo F, et al., 2021, The Optimal Timing of FDG-PET/CT in Non-Small Cell Lung Cancer Diagnosis and Staging in an Australian Centre. BMC PulmMed, 21: 209. doi: https://doi.org/10.1186/s12890-021-01564-w